WEALTH UNIVERSITY

[zigzagman]

Today's CTIC Conference Call at the Piper Jaffray Healthcare Conference:

http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-EventDetails&EventId=2575340&WebCastId=939681&StreamId=1406979

Study of Pixatrone according to the call:

* 95% of patients achieved an anticancer response.
* 77% of patients achieved a complete disappearance of detectable cancer.
* Overall survival at two years is 85%.
* The median duration of survival without cancer progression was over two years (25 months).
* The most common side effects were low levels of blood cells.

Radar this one again...There's a very slight possibility the FDA will announce the PUFDA decision before the April 23rd due date...That could make for an early "Pixmas" jokes the CEO...

I'm glad to hear your mom is stable Chartinator...